Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINE-101 first-in-human single ascending dose study in healthy volunteers
NCT07343323Phase 1Completed
- Sponsor
- KINE SCIENCES
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing KINE-101 with Placebo (2 arms). Primary endpoints: Adverse Events, Clinically Significant Abnormal Hematology and 6 more. Started Nov 2021; status: completed.
02
Drugs
KINE-101
Beyond the preview
Go deeper on NCT07343323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07343323.